Related Experiment Video
Updated: Jul 7, 2026
A New Technique for Quantitative Analysis of Hair Loss in Mice Using Grayscale Analysis
Published on: March 9, 2015
The Relative Efficacy and Safety of Monotherapies for Alopecia Areata: A Network Meta-Analysis Study
Aditya K Gupta1,2, Mary A Bamimore1, Paradi Mirmirani3,4,5
1Mediprobe Research Inc., London, Ontario, Canada.
Background:
Scant evidence exists for the relative efficacy of therapies for alopecia areata (AA)-including those approved by the Food and Drug Administration, namely, baricitinib, deuruxolitinib, and ritlecitinib.
Aims:
We determined the relative efficacy and safety of monotherapy with janus kinase inhibitors (JAKIs), apremilast, and dupilumab.
Methods:
Following a systematic review, we conducted Bayesian network meta-analysis (NMAs) that produced Surface Under the Cumulative RAnking (SUCRA) values and point estimates for pairwise relative effects; we also performed sensitivity analyses.
Results:
In total, regimens with eight various JAKIs were compared, namely, ruxolitinib, ATI-501, baricitinib, brepocitinib, deuruxolitinib, ivarmacitinib, ritlecitinib, and tofacitinib. Our analyses ranked "deuruxolitinib 12 mg twice daily for 24 weeks," the most efficacious insofar as "proportion of participants achieving SALT ≤ 20 at 24 weeks" (SALT20) (SUCRA = 92.6%), and "proportion of participants achieving SALT ≤ 10 at 24 weeks" (SALT10) (SUCRA = 97.7%). As per SALT20, the highest-ranked regimen was more efficacious than "baricitinib 2 mg once daily for 24 weeks" (odds ratio [OR] = 5.37, 95% credible interval [CI] = 1.59, 13.70, p < 0.05). Furthermore, the efficacy of the FDA-approved JAKIs exhibited a dose-dependent relationship; for instance, baricitinib 4 mg once daily for 24 weeks was more efficacious than "baricitinib 2 mg once daily for 24 weeks" in terms of SALT20 (OR = 2.25, 95% CI = 1.56, 3.21, p < 0.05). Results from our sensitivity analyses support that our base analyses were robust.
Conclusions:
We produced high-quality evidence on the comparative effectiveness of monotherapies for AA with various regimens of 8 JAKIs, including the FDA-approved ones. Our findings can improve clinicians' decision-making and update guidelines for medical practice.
Insights
Deuruxolitinib at 12 mg twice daily demonstrated superior efficacy for alopecia areata (AA) compared to other janus kinase inhibitors (JAKIs). This study provides crucial evidence for optimizing AA treatment strategies.
Area of Science:
- Dermatology
- Pharmacology
- Medical Statistics
Background:
- Limited data exists on the comparative effectiveness of alopecia areata (AA) treatments, including FDA-approved therapies.
- Janus kinase inhibitors (JAKIs) represent a significant advancement in AA management.
Purpose of the Study:
- To compare the efficacy and safety of various janus kinase inhibitors (JAKIs), apremilast, and dupilumab as monotherapies for alopecia areata (AA).
- To provide evidence-based guidance for clinical decision-making in AA treatment.
Main Methods:
- A systematic review and Bayesian network meta-analysis (NMA) were conducted.
- Surface Under the Cumulative Ranking (SUCRA) values and pairwise relative effects were calculated.
- Sensitivity analyses were performed to ensure the robustness of the findings.
Main Results:
- Deuruxolitinib (12 mg twice daily) ranked highest for efficacy, achieving significant proportions of participants with SALT ≤ 20 and SALT ≤ 10 at 24 weeks.
- Higher doses of FDA-approved JAKIs, such as baricitinib 4 mg, showed greater efficacy than lower doses (e.g., baricitinib 2 mg).
- The study compared eight different JAKI regimens, including FDA-approved options.
Conclusions:
- High-quality evidence was generated on the comparative effectiveness of various JAKI monotherapies for AA.
- Findings support improved clinical decision-making and potential updates to medical practice guidelines for AA.
- The study highlights the dose-dependent efficacy of certain JAKIs in treating AA.
